Dear Reader,
Gold has shattered records, soaring past $3,800 an ounce...
His research shows it could be triggered by a major event, eerily similar to what happened in the 1970s.
It's NOT inflation, fed rate cut expectations, escalating geopolitical tensions, or anything you're likely expecting.
And Doc believes you MUST own shares of his top gold stock.
He says you could 10x your money without touching a risky miner or a boring exchange-traded fund.
It's the centerpiece of Doc's full gameplan for this wild market, with extraordinary upside potential.
Click here for the full details on this developing gold story.
Regards,
Matt Weinschenk
Director of Research, Stansberry Research
2 Small-Cap Biotechs That Could Reward Patient Investors
Written by Chris Markoch. Date Posted: 12/12/2025.
In Brief
- Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculation and patience rarely go hand in hand. Nevertheless, if you're looking to invest in the small-cap biotech sector, patience is a requirement. Most of these companies are still in the clinical stage, meaning they have no commercially available drugs or therapeutics.
That also means negative earnings (they are not yet profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic.
Trump's "real estate deal for America" explained (Ad)
WARNING: Do Not Buy AI Stocks
While NVIDIA wobbles and the Magnificent 7 cool off, there's a backdoor AI play most investors are missing. It's not software. It's not chips. It's the physical infrastructure. The land, buildings, and power that make AI possible. Former Presidential Advisor Brad Thomas says Trump's Executive Orders are about to ignite a boom in this sector. And a small handful of companies are positioned to dominate. He names his top pick - completely free - in this time-sensitive video.
Even when a product advances through trials, profitability may still be years away. Only after reaching key commercialization milestones do these companies typically receive analyst coverage that attracts institutional investors.
Getting in on one of these medical stocks and seeing it succeed can feel like winning the lottery: investors could post 3x, 5x, or even 10x returns. Others may never pan out. That's why many penny-stock investors spread a lump sum evenly across numerous biotech names. If it's a numbers game, diversification can help manage the odds.
With that in mind, here are two small-cap biotech stocks that carry substantial risk but also the potential for outsized returns.
Mainz Biomed: Early Cancer Detection With High Upside Potential
Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular-diagnostics company that focuses on epigenetics-based tests for the early detection of cancer. Unlike many penny stocks in this space, Mainz Biomed has a commercially available product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe.
On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany's leading pioneers in digital health. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is significant.
The company is also in the early stages of developing a non-invasive, blood-based screening test for early pancreatic cancer detection. Mainz Biomed reported positive topline results in October, but commercial approval remains years away.
Risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains minimal. The company included "Going Concern" language in its Sept. 26 SEC filing. Since then, Mainz Biomed filed a $150 million mixed shelf registration. For now, that appears sufficient to keep MYNZ above $1 and avoid a delisting notice.
Mainz Biomed must generate enough revenue to move the needle, but if it succeeds, even a relatively small stake could produce a sizable return.
NanoViricides: High-Risk Antiviral Play With Breakthrough Potential
NanoViricides Inc. (NYSE: NNVC) is a micro-cap biotech pursuing a potentially disruptive antiviral approach—but it also carries the financial risks typical of early-stage companies.
The company is developing a novel class of antiviral therapies based on its proprietary "nanoviricide" platform. These drug candidates are designed to mimic human cell surfaces and lure viruses into binding with them, effectively neutralizing the pathogens before they can infect real cells. If validated in human trials, this would represent a new method for treating infectious diseases.
NanoViricides' pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has produced encouraging preclinical data suggesting strong antiviral activity.
Like many micro-cap biotechs, NanoViricides is pre-revenue and dependent on additional capital to advance its programs. Recent SEC filings show limited cash on hand, and investors should anticipate the possibility of future dilution.
Still, if even one candidate advances successfully into clinical development, the valuation upside could be meaningful. For investors with patience and a high tolerance for risk, NNVC represents a true moonshot in the antiviral space.
This message is a paid advertisement sent on behalf of Stansberry Research, a third-party advertiser of MarketBeat. Why did I receive this email message?.
This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.
If you need help with your account, please don't hesitate to email our South Dakota based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2025 MarketBeat Media, LLC. All rights protected.
345 North Reid Place, Suite 620, Sioux Falls, SD 57103. U.S.A..